Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Squarer Ron | Director | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 6,281 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Pelish Henry E. | Chief Scientific Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 14,350 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Pelish Henry E. | Chief Scientific Officer | Nuvalent, Inc. | OtherA · Grant or award from the company | 14,350 | $0.00 | $0 | 14,350Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Pelish Henry E. | Chief Scientific Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 41,100 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Pelish Henry E. | Chief Scientific Officer | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 22,393 | $124.00 | $2,776,732 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Oliger Christy J. | Director | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 6,091 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Oliger Christy J. | Director | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 1,324 | $124.00 | $164,176 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Balcom Alexandra | Chief Financial Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 14,350 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Balcom Alexandra | Chief Financial Officer | Nuvalent, Inc. | OtherA · Grant or award from the company | 14,350 | $0.00 | $0 | 14,350Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Balcom Alexandra | Chief Financial Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 41,100 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Balcom Alexandra | Chief Financial Officer | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 44,433 | $124.00 | $5,509,692 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Wheeler Cameron | Director | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 3,444 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Wheeler Cameron | Director | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 5,146 | $124.00 | $638,104 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Meyers Michael L. | Director | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 3,444 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Meyers Michael L. | Director | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 5,146 | $124.00 | $638,104 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Bogle Grant C. | Director | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 5,577 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Bogle Grant C. | Director | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 3,714 | $124.00 | $460,536 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Miller Deborah Ann | Chief Legal Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 14,350 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Miller Deborah Ann | Chief Legal Officer | Nuvalent, Inc. | OtherA · Grant or award from the company | 14,350 | $0.00 | $0 | 14,350Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Miller Deborah Ann | Chief Legal Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 41,100 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Miller Deborah Ann | Chief Legal Officer | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 18,534 | $124.00 | $2,298,216 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Turner Christopher Durant | Chief Medical Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 14,350 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Turner Christopher Durant | Chief Medical Officer | Nuvalent, Inc. | OtherA · Grant or award from the company | 14,350 | $0.00 | $0 | 14,350Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Turner Christopher Durant | Chief Medical Officer | Nuvalent, Inc. | OtherD · Sale or transfer back to the company | 41,100 | Not reported | No price reported | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 | |
| Turner Christopher Durant | Chief Medical Officer | Nuvalent, Inc. | OtherU · Shares tendered in a change of control | 31,530 | $124.00 | $3,909,720 | 0Direct | Form 4 filed 15 Jul 2026, on sec.gov (opens in a new tab)Filed 15 Jul 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.